60 Degrees Pharmaceuticals Inc
SXTP
View Detailed Chart
1.360USD
-0.090-6.21%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.00MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.21%
5 Days
-2.86%
1 Month
+6.25%
6 Months
-31.66%
Year to Date
-78.91%
1 Year
-79.88%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
7.000
Target Price
+379.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 33.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 681.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 36.38.
Overvalued
The company’s latest PE is -0.02, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 103.95K shares, increasing 2.26% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 81.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Ticker SymbolSXTP
Company60 Degrees Pharmaceuticals Inc
CEODr. Ll S. Dow, Ph.D.
Websitehttps://60degreespharma.com/
Related Instruments
-1.40%
+1.17%
+0.19%
+0.48%
-1.02%
-0.71%
-0.04%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.29%
+1.22%
+0.92%
-0.92%
-0.23%
-0.83%
-1.12%
+0.31%
